← All trials
NCT02580474
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2016
- Primary completion
- Apr 1, 2017
- Completion date
- Apr 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Catholic University of KoreaLead sponsor
- Catholic University of KoreaSponsor investigator
- Bristol-Myers SquibbCollaborator
- Dankook UniversityCollaborator
- Catholic University of KoreaCollaborator
- Yonsei UniversityCollaborator
- Chungnam National UniversityCollaborator
- Korea UniversityCollaborator
- Eulji UniversityCollaborator
- Konyang UniversityCollaborator
- Cheongju St. Mary's HospitalCollaborator
- Konkuk UniversityCollaborator
- Soonchunhyang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.